Eiji Honda

This inventor holds 16 USPTO granted patents and 6 published patent applications, plus 2 CIPO patents and 4 EPO patents. Top assignees: Takeda Pharmaceutical Company Limited, Prism Biolab Corporation. Active years: 2010-2026.

USPTO Granted Patents = 16 (Patent Applications = 6)

% Patents Active = 68.8

CIPO Patents = 2

EPO Patents = 4 (Patent Applications = 4)

Average Co-Inventor Count = 6.3

ph-index = 5

Forward Citations = 65(Granted Patents)

Location History:

Osaka, JP (2010)
Kanagawa, JP (2013 - 2022)

Company Filing History:

15 out of 1,226

Takeda Pharmaceutical Company Limited

patents

1 out of 3

Prism Biolab Corporation

patents

Years Active: 2010-2026

Loading Chart...

16 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12703707 - Heterocyclic compounds (2026-08-11),

2. 11279713 - Heterocyclic compound and use thereof (2022-03-22),

3. 10654874 - Heterocyclic compound and use thereof (2020-05-19),

4. 9884875 - Heterocyclic compound and use thereof (2018-02-06),

5. 9499568 - Heterocyclic compound and use thereof (2016-11-22),

6. 9493484 - Heterocyclic compound and use thereof (2016-11-15),

7. 9226921 - Fused heterocyclic compounds as phosphodiesterases (PDES) inhibitors (2016-01-05),

8. 9150591 - Heterocyclic compound and use thereof (2015-10-06),

9. 9029388 - Condensed heterocyclic compound (2015-05-12),

10. 8940758 - Fused heterocyclic compounds (2015-01-27),

11. 8916551 - Heterocyclic compound and use thereof (2014-12-23),

12. 8846713 - Fused heterocyclic compounds as phosphodiesterases (PDEs) inhibitors (2014-09-30),

13. 8778934 - Heterocyclic compound and use thereof (2014-07-15),

14. 8575154 - Heterocyclic compound and use thereof (2013-11-05),

15. 8563575 - Fused heterocyclic compounds (2013-10-22),

Title: Eiji Honda: Innovator in Pharmaceutical Chemistry

Introduction

Eiji Honda is a prominent inventor based in Kanagawa, Japan, known for his significant contributions to pharmaceutical chemistry. With a total of 15 patents to his name, he has made remarkable advancements in the field, particularly in the development of compounds that target neurological disorders.

Latest Patents

Among his latest patents is a heterocyclic compound that exhibits an AMPA receptor potentiating action. This compound is represented by a specific formula, as detailed in the patent specifications. It has been identified as a potential prophylactic or therapeutic drug for various conditions, including depression, schizophrenia, Alzheimer's disease, and attention deficit hyperactivity disorder (ADHD). The innovative nature of this compound highlights Honda's commitment to addressing critical health issues through scientific research.

Career Highlights

Eiji Honda has worked with notable companies in the pharmaceutical industry, including Takeda Pharmaceutical Company Limited and Asahi Kasei Chemicals Corporation. His experience in these organizations has allowed him to collaborate with leading experts and contribute to groundbreaking research in drug development.

Collaborations

Some of his notable coworkers include Shinji Nakamura and Masashi Toyofuku, who have also made significant contributions to the field of pharmaceutical chemistry. Their collaborative efforts have further advanced the research and development of innovative compounds.

Conclusion

Eiji Honda's work exemplifies the impact of innovation in the pharmaceutical industry. His patents and collaborations reflect a dedication to improving therapeutic options for patients with neurological disorders. His contributions continue to inspire future advancements in the field.